BioSpace News Archive

Company Presentation on Tuesday, June 4 at 3:40pm PT to Highlight its Core Nutritional Products

G.research will host its 11th Annual Entertainment & Broadcasting Conference on June 6 in New York City.

Heidi Hagen and Dr. Howard Grimes Named Strategic Advisors

Dr Mark Albertella appointed VP Translational Oncology

RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory confirmation) by 66.4% (p=0.003) as compared to placebo among Phase 2b participants 65 years of age and older with asthma

Acquisition Includes Novel Late-Stage Renal Cell Carcinoma Candidate, PT2977

Theravance Biopharma, Inc. reported data from the exploratory Phase 1b study of the gut-selective pan-Janus kinase inhibitor, TD-1473, in an oral presentation at Digestive Disease Week 2019.

ZyVersa’s lead anti-inflammatory candidate is a novel monoclonal antibody targeting the ASC component of inflammasomes, inhibiting both the intracellular and extracellular inflammatory response cascade for treatment of people with debilitating inflammatory diseases

Entac Medical Inc. announced that an abstract entitled, Prospective Analysis of an Acoustic Biomarker for Successful Early Oral Re-feeding Following Major Abdominal Surgery, has been accepted for podium presentation at the annual meeting of the American College of Surgeons Clinical Congress in October 2019.

The Janssen Pharmaceutical Companies of Johnson & Johnson presented a new cost-efficiency analysis at the International Society for Pharmacoeconomics and Outcomes Research Annual Meeting that illustrates the value of SPRAVATO™ CIII nasal spray for treatment-resistant depression, for patients, U.S. payers, and society.